Protocol Library

Each card lists peptide research notes — vial size, example research dose range, reconstitution example, frequency example, cycle length example, and risk level. All entries are educational. Not medical advice.

Research use only. Educational content. Not medical advice, diagnosis, treatment, or a personal recommendation. Not intended for human consumption. Always discuss with a qualified healthcare professional.

5-Amino-1MQ

low risk

Researched as an NNMT inhibitor in metabolic studies.

Vial
50 mg
Dose
50–150 mg daily (research literature, oral)
Freq
Once daily (research example)
Cycle
4–8 weeks (research example)
weight-managementenergy-metabolism

AICAR

high risk

Used in research contexts to study AMPK pathway activation, mitochondrial biogenesis and substrate utilization.

Vial
50 mg lyophilized vial
Dose
Research literature ranges vary widely; educational example only.
Freq
Protocol-dependent in research.
Cycle
Short cycles in published research designs.
energy-metabolismperformance

Bioglutide (NA-931)

moderate risk

Studied in research contexts for incretin pathway activity and metabolic markers.

Vial
5 mg lyophilized vial
Dose
Educational research dose example only.
Freq
Weekly in research designs.
Cycle
Multi-week educational examples.
weight-managementenergy-metabolism

Cagrilintide

moderate risk

Researched for amylin receptor activity, gastric emptying and satiety endpoints.

Vial
5 mg lyophilized vial
Dose
Commonly discussed research range: 0.3–2.4 mg weekly.
Freq
Weekly.
Cycle
12–20 week educational example.
weight-managementenergy-metabolism

L-Carnitine

low risk

Studied for its role in fatty-acid transport, mitochondrial metabolism, endurance research and metabolic energy research.

Vial
200 mg/ml ampoule
Dose
Published research literature references a broad range; commonly cited examples include 500–2000 mg per research day.
Freq
Often daily in research scheduling examples.
Cycle
Continuous research periods are common.
related-compoundsenergy-metabolismperformance

Lipo-C

low risk

Studied for hepatic lipid metabolism research contexts.

Vial
Multi-dose vial (varies)
Dose
Educational research range varies by formulation.
Freq
Weekly research administration example.
Cycle
4–12 week educational example.
weight-managementenergy-metabolism

Mazdutide

moderate risk

Investigated for combined GLP-1 and glucagon receptor activity on metabolic endpoints.

Vial
5 mg lyophilized vial
Dose
Commonly discussed research range: 1.5–9 mg weekly.
Freq
Weekly.
Cycle
12–24 week educational example.
weight-managementenergy-metabolism

MOTS-c

low risk

Researched in mitochondrial and metabolic regulation contexts.

Vial
10 mg
Dose
5–10 mg weekly (research literature)
Freq
2–3x weekly (research example)
Cycle
4–8 weeks (research example)
energy-metabolismlongevityperformance

NAD+

moderate risk

Researched in NAD+ metabolism and cellular energy contexts.

Vial
500 mg
Dose
100–500 mg per use (research literature)
Freq
1–3x weekly (research example)
Cycle
4–8 weeks (research example)
longevityenergy-metabolism

Retatrutide

moderate risk

Researched as a triple receptor agonist for metabolic and bodyweight studies.

Vial
10 mg
Dose
1 mg – 12 mg weekly (research literature)
Freq
Once weekly (research example)
Cycle
12+ weeks (research example)
weight-managementenergy-metabolism

Semaglutide

moderate risk

Commonly researched in studies of appetite regulation, satiety, and glucose metabolism.

Vial
5 mg
Dose
0.25 mg – 2.4 mg weekly (research literature)
Freq
Once weekly (research example)
Cycle
12+ weeks (research example)
weight-managementenergy-metabolism

SS-31 (Elamipretide)

moderate risk

Researched in mitochondrial cardiolipin and energy production contexts.

Vial
10 mg
Dose
1–5 mg daily (research literature)
Freq
Once daily (research example)
Cycle
4–8 weeks (research example)
energy-metabolismlongevity

Survodutide

moderate risk

Investigated for combined incretin and glucagon receptor activity.

Vial
5 mg lyophilized vial
Dose
Commonly discussed research range: 0.3–4.8 mg weekly.
Freq
Weekly.
Cycle
12–24 week educational example.
weight-managementenergy-metabolism

Tirzepatide

moderate risk

Studied for dual GIP/GLP-1 receptor activity in metabolic research contexts.

Vial
10 mg
Dose
2.5 mg – 15 mg weekly (research literature)
Freq
Once weekly (research example)
Cycle
12+ weeks (research example)
weight-managementenergy-metabolism
Verified Research Supplier

Looking for a research supplier?

Enhanced Performance is a separate research supply platform. Visiting or purchasing is optional and not required to use PepToolbox.

Disclosure: Enhanced Performance is a separate platform connected to the owner of this website. Purchasing is optional and not required to use this tool.